Incyte Agrees to $1.25 Billion Acquisition to Expand Hematology Pipeline
WILMINGTON, DE — Incyte has agreed to acquire Vega Therapeutics for $1.25 billion upfront in a deal that would add a late-stage treatment candidate for von Willebrand disease to the …
Incyte Agrees to $1.25 Billion Acquisition to Expand Hematology Pipeline Read More